Effects of sporoderm-broken germination activated ganoderma spores on treatment of spinal cord injury

• US 7,132,103 B2
• Filed: 08/01/2003
• Issued: 11/07/2006
• Est. Priority Date: 08/01/2003
• Status: Expired due to Fees

• Current Assignee: Enhan Technology Holdings International Company Limited
• Original Assignee: Enhan Technology Holdings International Company Limited
• Inventors: Chung, Chee-Keung, Tong, Siu-Kan
• Primary Examiner(s): TATE, CHRISTOPHER ROBIN
• Application Number:
  US10/631,809
• Publication Number:
  US 20050025785A1
• Time in Patent Office: 1,194 Days
• Field of Search: 424/195.15
• US Class Current: 424/195.15
• CPC Class Codes: A61K 36/074 Ganoderma
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides a method for treating patients with spinal cord injury by administering germination activated Ganoderma lucidium spores (GASP) to the patients. The GASP are sporoderm-broken. The GASP promote axon regeneration and improve motor neuron survival in the injured spinal cord.

Claims

1. A method for treating a mammal with spinal cord injury comprising:

administering an effective amount of sporoderm-broken germination activated Ganoderma spores (GASP) to a mammal having spinal cord injury,

wherein said GASP are prepared by;

soaking Ganoderma spores in a solution to cause said Ganoderma spores to germinate,

placing said germinated Ganoderma spores in a culture box at a relative humidity of 65-98% and a temperature of 18-48°

C. to cause said germinated Ganoderma spores to activate; and

breaking said germination activated Ganoderma spores with an enzyme with cell wall dissolving property or with a mechanical force to produce said GASP.

2. The method according to claim 1, wherein said GASP are orally administered to said mammal.

3. The method according to claim 1, wherein said GASP are administered to said mammal within about 1 day of said spinal cord injury.

4. The method according to claim 1, wherein said mammal is human.

5. The method according to claim 1, wherein said spinal cord injury is caused by compression or severance of the spinal cord.

6. The method according to claim 1, wherein said spinal cord injury is caused by a trauma.

7. The method according to claim 5, wherein the spinal cord injury is caused by severance of a ventral root of the spinal cord.

8. The method according to claim 5, wherein the spinal cord injury is caused by severance or crush of the sciatic nerve.

9. The method according to claim 1, wherein said spinal cord injury is caused by a disease.

10. The method according to claim 9, wherein said disease is polio, spina bifida, or Friedreich'"'"'s Ataxia.

11. The method according to claim 1, wherein said spinal cord injury is caused by damage or death of neurons within said injured spinal cord.

12. The method according to claim 11, wherein said neurons are motor neurons.

13. The method according to claim 1, wherein said spinal cord injury is caused by crush of axons with said injured spinal cord.

14. The method according to claim 1, wherein said effective amount of said GASP is about 0.5-15 g per kg of body weight per day.

15. A method for improving survival of neurons after a spinal cord injury comprising:

administering an effective amount of GASP to a mammal having said spinal cord injury,

wherein said GASP are prepared by;

soaking Ganoderma spores in a solution to cause said Ganoderma spores to germinate,

placing said germinated Ganoderma spores in a culture box at a relative humidity of 65-98% and a temperature of 18-40°

C. to cause said germinated Ganoderma spores to activate; and

breaking said germination activated Ganoderma spores with an enzyme with cell wall dissolving property or with a mechanical force to produce said GASP.

16. The method according to claim 15, wherein said mammal is human.

17. The method according to claim 15, wherein said GASP are administered to said mammal within 1 day of said spinal cord injury.

18. The method according to claim 15, wherein said neuron is a motor neuron in said injured spinal cord.

19. The method according to claim 15, wherein said effective amount of said GASP is about 0.5-15 g per kg of body weight per day.

20. A method for promoting axon regeneration in a spinal cord injury comprising:

administering an effective amount of GASP to a mammal having said spinal cord injury,

wherein said GASP are prepared by;

soaking Ganoderma spores in a solution to cause said Ganoderma spores to germinate,

placing said germinated Ganoderma spores in a culture box at a relative humidity of 65-98% and a temperature of 18-40°

C. to cause said germinated Ganoderma spores to activate; and

breaking said germination activated Ganoderma spores with an enzyme with cell wall dissolving property or with a mechanical force to produce said GASP.

21. The method according to claim 20, wherein said GASP are administered to said mammal within 1 day of said spinal cord injury.

22. The method according to claim 20, wherein said effective amount of said GASP is about 0.5-15 g per kg of body weight per day.